This page contains a Flash digital edition of a book.
The Neurogenic Component of Cutaneous Toxicities Induced by Chemotherapy – New Solutions


Figure 3: Acneiform Eruption Before and After Treatment


A


A: Acneiform eruption induced by cisplatinum + cetuximab regimen after one month of treatment


Figure 4: Deep Heel Fissures on Right Foot Before and After Treatment


A


A: Deep heel fissures on right foot induced by cetuximab + carboplatin regimen over six months


B


B: Result after one week of topical treatment with Evozac Solution spray twice a day


B


B: Result after two weeks of topical treatment with Evoskin spray (for (two days) and then Evoskin Gel cream twice a day.


C


C: Result after 26 days with the same regimen


expressing this receptor. The incapacitating fissured conditions induced by this molecule are often reported in the literature. The introduction of an effective product without side effects for topical use in a rapid timespan of several days for resolution of heel fissures observed during chemotherapy offers the patient a significant functional and aesthetic benefit by improving his or her quality of life and contributing to better adherence to the chemotherapy regimen.


presented with deep heel fissures on both feet with pronounced hyperkeratosis and significant discomfort when applying pressure to the heel (see Figure 4A). He had been treated for cancer of the right maxillary sinus by the combination of carboplatine and cetuximab (Erbitux) for six months. In order to reduce the fissures, Evoskin Solution Spray was sprayed on the heels morning and night for the first two days, then Evoskin Gel Cream was applied as a follow-up at the same dosage. Evoskin Solution Spray and Gel Cream are formulated from mineral elements contained in Evaux thermal spring water (lithium, manganese, strontium). Two weeks after starting application of Evoskin, the fissures were closing and their haemorrhagic nature had disappeared, and the discomfort under pressure had eased (see Figure 4B). No intolerance to ungual Evoskin Solution Spray and Gel Cream was reported by the patient during the application period.


Cetuximab (Erbitux), an EGF receptor inhibitor, is a frequently used chemotherapeutic agent, especially in the treatment of ENT cancers


1. Wasner G, Hilpert F, Schattschneider J, et al., Docetaxel-induced nail changes – a neurogenic mechanism: a case report, J Neur Oncol, 2002;58:167–74.


2. Boisnic S, Branchet MC, Chanez JF, Evaluation of Case Report 4


This final case report considers the mucositis scoring before and after applying EVOMUCY® Spray during ten days in four patients suffering from squamous cell carcinoma (SCC) or adenocarcinoma and treated by Taxotere® + 5-FU + cisplatin association. Oral Mucositis Assessment Scale (OMAS), World Health Organization (WHO) and National Cancer Institute Common Toxicity Criteria (NCI-CTC) score ranges were maintained on baseline value (WHO score range) or slightly increased (OMAS and NCI-CTC range) in three patients. Impact on pain and diet was also improved during EVOMUCY Spray use. Completion of this study is in progress.3


Conclusion


By underlining the involvement of neuromediators in cutaneous problems, particularly following chemotherapy, Evolife Laboratories offers complete, specific and innovative solutions for cutaneous and muco-cutaneous side effects induced by chemotherapy. n


the inhibition of human sébocytes proliferation stimulated by substance P and corticotropin- releasing hormone by mineral constituents in Evaux thermal spring water, Nouv Dermatol, 2004;23:569–75. 3. Lalla RV, Choquette LE, Chanez JF, Sharan S, An


open-label study of EVOMUCY® Spray for chemotherapy- induced oral mucositis, Poster presented at the International Symposium Supportive Care in Cancer MASCC/ISOO, Vancouver, Canada, 24–26 June 2010.


EUROPEAN ONCOLOGY & HAEMATOLOGY


15


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92